A study conducted by researchers at Mayo Clinic shows that obese patients with specific genetic makeup had enhanced response to the weight loss drug sibutramine, while others who lack these genetic factors lost little or no weight. The findings are published in the October issue of Gastroenterology (http://www.gastrojournal.org).